Do you consider ADT intensification with enzalutamide or abiraterone in patients receiving adjuvant radiation with ADT?  

Are there clinical features (post-op PSA, Decipher score, pN+, pT3, etc) that would inform your decision?



Answer from: Radiation Oncologist at Community Practice

Answer from: Medical Oncologist at Academic Institution